Nu-Med Grupa

Established: 2012

Country: Poland

Region: CEE

Investors: Enterprise Investors

Nu-Med Grupa is a Polish chain of oncology clinics. The company provides imaging diagnostics, radiotherapy and chemotherapy treatment to cancer patients at four clinics located in Katowice (southern Poland), Elbląg (northern Poland), Tomaszów Mazowiecki (central Poland) and Zamość (eastern Poland).

All the clinics have contracts with the National Health Fund (NFZ). In 2023, the last full year of EI’s investment, Nu-Med carried out close to 7,700 radiotherapy procedures and treated more than 600 brachytherapy patients. During EI’s investment the group provided critical care to almost 70,000 patients. The company also actively promotes public awareness of cancer prevention. Nu-Med organises mammography events (400+ patients in 2023), prophylactic workshops and other educational and oncological screening events (c. 1,000 patients).

Paweł Paczkowski

CEO - Nu-Med Grupa

With EI’s support, we built Nu-Med from the ground up into a network of modern oncology clinics. Over the course of our partnership, we provided advanced cancer care to nearly 70,000 patients across several underserved regions in Poland.

~70k

patients

674

FTE headcount

clinics established across underserved regions of Poland

Key achievements

Built a leading oncology care provider in Poland as a greenfield investment.
Developed four treatment centers across underserved regions in Poland.
Delivered radiotherapy, chemotherapy and diagnostics to nearly 70,000 cancer patients.
Introduced advanced medical technologies, including PET-CT, MRI, mammography, and LINAC.

Funding history

Made an initial greenfield investment in Katowice in 2012.
Structured the funding to support expansion and acquisitions.
Completed three bolt-on acquisitions to expand the network.
Exited to trade buyer Affidea in 2024.

Employment impact

Grew from zero to 674 full-time employees.
Created high-skilled medical jobs across four regions in Poland.
Supported workforce development through state-of-the-art medical technologies and partnerships with hospitals.